RNAi-mediated gene silencing in non-human primates

By Tracy S. Zimmermann, Amy C. H. Lee, Akin Akinc, B. Bramlage, D. Bumcrot, M. Fedoruk, J. Harborth, J. Heyes, L. Jeffs, Matthias J John and 19 more. Nature, 2006

1,368 citations recorded by the source corpus.

Subfields: Cancer Research, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/af7ea2b6a9967b509e9e627ffb3a9592b2f31216

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

1. Robert Langer
2. L. Aagaard
3. M. Manoharan
4. John J. Rossi
5. Theresa M. Allen
6. P. McCray
7. B. Davidson

In Molecular Biology

1. John J. Rossi
2. Francis C. Szoka Jr.
3. Robert Langer
4. Daniel G. Anderson
5. P. Cullis
6. P. McCray
7. M. Manoharan
8. Martin Egli

Citations in the corpus

• Delivery of siRNA Therapeutics: Barriers and Carriers (2010, background): “In cynomolgus monkeys, a single intravenous injection of ApoB siRNA encapsulated in pegylated solid nucleic acid lipid particles resulted in dose-dependent reductions of ApoB mRNA and protein in the liver and reductions of serum cholesterol and low-density lipoprotein levels lasting for 11 days ( 92”
• Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates (2008, methodology): “To confirm that the reduction in PCSK9 transcript observed in rodents was because of a siRNA mechanism, liver extracts from either treated or control rats were subjected to rapid amplification of cDNA ends (5 -RACE), a method previously used to demonstrate that siRNA-mediated cleavage occurs (21, 22”
• Lipid-like materials for low-dose, in vivo gene silencing (2010, background): “Such doses are comparable to those required by stable nucleic acid lipid particle (SNALP) formulations, another delivery system which has shown utility for siRNA delivery in nonhuman primates (14).”
• RNAi therapeutics: a potential new class of pharmaceutical drugs (2006, methodology): “made use of siRNA duplexes formulated in stable nucleic acid lipid particles (SNALPs 39 ) to recapitulate the silencing of apoB in mice 73 .”
• Liposomal drug delivery systems: from concept to clinical applications. (2013, background): “venous injection at dose levels of 1 mg siRNA/kg body weight [208].”
• Lipid-based Nanoparticles for Nucleic Acid Delivery (2007, background): “These results strongly support that NP can effectively deliver therapeutic amounts of siRNA (67).”